HEPA News and Press, Hepion Pharmaceuticals Inc. From 09/13/21

Pro-C3 and ALT reductions point to anti-inflammatory and antifibrotic effects of CRV431 PK-PD models successfully predict early reductions in Pro-C3 and ALT Hepion’s proprietary AI-POWR™ and machine learning accurately predict CRV431 responders Anti...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! The weekend has come and gone and that means it’s time to get back into investing with a look at Monday’s biggest pre-market stock movers. Source: f11photo/Shutterstock.com We...

3 Hot Penny Stocks to Watch on Robinhood Right Now With so many penny stocks to buy on Robinhood, making the choice can be complicated. But, because there are so many options, there are also plenty of opportunities to make money with penny stocks on Robinhood . To understand it furt...

EDISON, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NAS...

Soligenix (NASDAQ:SNGX) +26% FDA Grants soligenix orphan drug designation for the treatment of T-cell lymphoma Eloxx Pharmaceuticals (NASDAQ:ELOX) +22% announces fast track designation for ELX-02 for the treatment of cystic fibrosis patients with nonsense mutations Cardiff Oncology ...

Are These Penny Stocks On Your List Right Now? In this article, we will take a look at 4 penny stocks with upcoming events very soon. How do we know this? One of the great things about certain industries is that companies will pre-announced key dates well in advance. Biotech companies a...

Hepion Pharmaceuticals is a promising candidate in the race for an effective drug for treating NASH. Although still in a very early phase of trials, CRV431 has presented very promising preclinical results. The ALT reduction obtained in last phase IIa trial outperformed all competi...

EDISON, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the ...

Hepion Pharmaceuticals (HEPA) shares fall more than 7% premarket despite announcing that its CRV431 treatment met all primary endpoints in a mid-stage trial of patients with non-alcoholic steatohepatitis ("NASH").The study was a Phase 2a randomized, multi-center, plac...

Safety, Tolerability and Pharmacokinetics (“PK”) Primary Endpoints Met Reductions in Liver Transaminases Indicate Dose-Related Improvements in Key NASH Biomarker Concentration-Effect Relationship Demonstrated for ALT Reductions Multiomic Analyses an...